WINNIPEG,
MB, Jan. 11, 2023 /CNW/ - Waverley Pharma Inc.
("Waverley Pharma" or the "Company") (TSXV: WAVE), a Canadian
pharmaceutical company, is pleased to provide an update on the
status of its oncology focused PARP-1 inhibitor program. Based on
growing interest in new PARP-1 inhibitors with selective activity
against PARP-1 over PARP-2, the Company has renewed its focus on
completing its PARP-1 pre-clinical development program, which is at
the lead optimization stage. The current lead compound has
single digit nanomolar activity and significant selectivity to
PARP-1 over PARP-2.
It is postulated that the effect of chemotherapy
and radiation therapy is dampened by DNA repair enzymes 1 Poly
(ADP-Ribose) Polymerase-1 (PARP-1) which belongs to the PARP family
of enzymes and is involved in the detection and repair of DNA
damage. PARP-1 inhibitors are a class of anti-cancer agents
targeting DNA repair mechanism. The inhibition of PARP-1 is of
clinical importance in various types of cancer. PARP-1
inhibitors have shown great potential to target high-grade ovarian
cancers and triple-negative breast cancers which are resistant to
current treatment. PARP-1 inhibitors can be used as a monotherapy
to selectively kill cancer cells and in combination with other
therapies.
About Waverley Pharma
Waverley Pharma is a pharmaceutical company
focused on the development and commercialization of safe,
effective, and affordable cancer therapeutics in the EU,
United Kingdom and North American
markets. The Company, through its subsidiary, is currently selling
four generic oncology products in the United Kingdom, namely capecitabine,
temozolomide, pemetrexed and bortezomib. In addition, the Company
has received marketing approval for pemetrexed and bortezomib in
Europe and the United States. Waverley Pharma is
committed to providing patients with affordable prescription
medicines that lower healthcare costs and provide a better quality
of life. For more information on Waverley Pharma please visit
www.waverleypharma.com.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Forward Looking Information: Statements
contained in this press release that are not statements of
historical fact, including, without limitation, statements
containing the words "believes", "may", "plans", "will",
"estimates", "continues", "anticipates", "intends", "expects" and
similar expressions, may constitute "forward-looking information"
within the meaning of applicable Canadian and U.S. federal
securities laws (such forward-looking information and
forward-looking statements are hereinafter collectively referred to
as "forward-looking statements"). Forward-looking statements
include the future development of the Company's PARP-1 inhibitor
program, tender awards and other estimates, analysis and opinions
of management of the Company made in light of its experience and
its perception of trends, current conditions and expected
developments, as well as other factors which the Company believes
to be relevant and reasonable in the circumstances. Inherent in
forward-looking statements are known and unknown risks,
uncertainties and other factors beyond the Company's ability to
predict or control that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements, and as such, readers are cautioned not to place undue
reliance on forward-looking statements. Such risk factors include,
among others, the Company's potential product revenues, stage of
development, additional capital requirements, risks associated with
obtaining regulatory approval to market the Company's products, the
ability to protect its intellectual property, dependence upon
collaborative partners, changes in government regulation or
regulatory approval processes, and rapid technological change in
the industry. Such statements are based on a number of assumptions
which may prove to be incorrect, including, but not limited to,
assumptions about: general business and economic conditions; the
impact of changes in Canadian-US dollar and other foreign exchange
rates on the Company's revenues, costs and results; the timing of
the receipt of regulatory and governmental approvals for the
Company's research and development projects; the availability of
financing for the Company's commercial operations and/or research
and development projects, or the availability of financing on
reasonable terms; the uncertainties associated with the acceptance
and demand for new products and market competition. The foregoing
list of important factors and assumptions is not exhaustive. The
Company undertakes no obligation to update publicly or otherwise
revise any forward-looking statements or the foregoing list of
factors, other than as may be required by applicable legislation.
Additional discussion regarding the risks and uncertainties
relating to the Company and its business can be found in the
Company's other filings with the applicable Canadian securities
regulatory authorities.
SOURCE Waverley Pharma Inc.